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Abstract
Background: Urinary and (peripheral and central) intravenous catheters are widely used in hospitalized patients.
However, up to 56% of the catheters do not have an appropriate indication and some serious complications with the
use of these catheters can occur. The main objective of our quality improvement project is to reduce the use of catheters
without an appropriate indication by 25–50%, and to evaluate the affecting factors of our de-implementation strategy.
Methods: In a multicenter, prospective interrupted time series analysis, several interventions to avoid inappropriate use of
catheters will be conducted in seven hospitals in the Netherlands. Firstly, we will define a list of appropriate indications for
urinary and (peripheral and central) intravenous catheters, which will restrict the use of catheters and urge catheter
removal when the indication is no longer appropriate. Secondly, after the baseline measurements, the intervention will
take place, which consists of a kick-off meeting, including a competitive feedback report of the baseline measurements,
and education of healthcare workers and patients. Additional strategies based on the baseline data and local conditions
are optional. The primary endpoint is the percentage of catheters with an inappropriate indication on the day of data
collection before and after the de-implementation strategy. Secondary endpoints are catheter-related infections or other
complications, catheter re-insertion rate, length of hospital (and ICU) stay and mortality. In addition, the cost-effectiveness
of the de-implementation strategy will be calculated.
Discussion: This study aims to reduce the use of urinary and intravenous catheters with an inappropriate indication, and
as a result reduce the catheter-related complications. If (cost-) effective it provides a tool for a nationwide approach to
reduce catheter-related infections and other complications.
Trial registration: Dutch trial registry: NTR6015. Registered 9 August 2016.
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Background
Healthcare-associated infections (HAIs) are associated
with an increased mortality, a longer duration of hospital
stay, which results into an increase in substantial costs.
The use of invasive medical devices (e.g., urinary cathe-
ters, peripheral intravenous catheters (PIVCs) and
central venous catheters (CVCs)) are important risk
factors for the development of HAIs, which have preva-
lence of 7.1% measured in a combined point prevalence
survey in Europe [1]. So an efficient way to reduce HAIs
is to avoid insertion of catheters without an appropriate
indication and to reduce the number of catheter days.
In general hospitals 15–25% of patients have an
indwelling urinary catheter during their hospital stay.
Urinary tract infections are accountable for 40% of all
nosocomial infections in Western world hospitals, and
71–80% of these patients had a urinary catheter [2–4].
Nevertheless, the incidence of unwarranted placement of
urinary catheters in hospitalized patients is 14–65% [5–10].
PIVCs are the most frequently used invasive medical
devices in hospitalized patients. However, 25–56% of the
PIVCs inserted in the Emergency Department are in-
appropriate or even unused [11–16]. In a recent study of
internal medicine departments in Spain 81.9% of the
patients had one or more PIVCs, of which 19% were no
longer necessary [17]. A PIVC can cause serious adverse
events, with an incidence rate of catheter-associated
bloodstream infection of 0.1% (0.5 per 1000 catheter
days) [18].
Central line-associated bloodstream infections (CLABSIs)
are a major problem in intensive care units (ICUs). A
meta-analysis shows that implementation of central line
bundles to reduce the incidence of CLABSIs are effective
and cost saving in ICUs [19].
Intervention studies to prevent catheter-related infections
Previous research suggests that multiple and well-
organized interventions could reduce the number of
HAIs. In a pilot study in our university hospital in the
Netherlands 89.2% of the initial indications for urinary
catheter use were appropriate. However, after 2–3 days
the initial indication was mostly no longer present,
resulting into an inappropriate indication, but not to a
removal of the catheter. After education and daily
assessment of the indication of urinary catheters, the
duration of catheterization reduced from 1009 to
672 days in 149 patients (pre-intervention n = 74, post-
intervention n = 75), and the number of catheter-
associated urinary tract infections (CAUTI) decreased
from 4 to 0 infections per 1000 catheter days (p = 0.04).
Thereby the median length of hospital stay reduced from
13 to 9 days [20]. Very recently, a national program
(dissemination of information to sponsor organizations
and hospitals, data collection, and guidance on key
technical and socioadaptive factors) in 603 US hospitals
reduced CAUTI rates by 22% in non-ICUs [21].
Only a few studies evaluated the effect of interventions
to improve the appropriate use of PIVCs. In 1994 a
quality improvement project in the internal medicine
wards of Minnesota reduced inappropriate use of PIVCs
by 63% (43% vs 27%) [22]. Education and feedback to
improve PIVC care significantly reduced the PIVC-
associated bloodstream infections from 2.2 to 0.44 per
10.000 patients days in 10 non-ICUs [23]. Furthermore,
in a general hospital in Spain the use of unnecessary
peripheral and central venous lines decreased from 22.9
to 7.1% after a 1-year training program [24].
A multifaceted ‘bundle’ approach (education, hospital
protocol, national program, and checklist intervention)
to control CVC-associated bloodstream infection in an
internal medicine department in Spain showed a de-
crease of 63.1% (14.1 to 5.2 per 1000 catheter days) [25].
Prevention of HAIs is an important part of the todays
medical practice. However, the risks of the use of urinary
catheters and mainly PIVCs are widely underestimated,
and in the Netherlands no nationwide program to
reduce the catheter-related infections is present.
Methods and Design
Objectives
In this de-implementation study we aim for a 25–50%
reduction of the number of urinary and (peripheral and
central) intravenous catheters without an appropriate
indication, which will lead to a reduction of the number
of catheter days and catheter-related complications.
Study design and setting
The study design is a multicenter, prospective inter-
rupted time series (Fig. 1), which will take place in seven
hospitals in the Netherlands (three university and four
general hospitals). We aim to reduce 25–50% of the
catheters without an appropriate indication by a
Fig. 1 Interrupted time series for appropriate use of catheters
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de-implementation strategy of multiple interventions.
The clinical data collection will be once per 14 days
during 8 months in both the pre- and post-intervention
period. During these measurement days all patients with
a urinary and/or (peripheral and/or central) intravenous
catheter inserted during the hospital stay will be
enrolled. The de-implementation strategies will start
during a transition period of 4 months, while no patients
will be included.
Appropriate use of catheters
We defined a list of valid indications for urinary and
intravenous catheter placement, based on the literature
(Table 1) [26–29]. All other indications are defined as
inappropriate.
Definition of catheter-related infections
We will use the definitions by Centre for Disease Con-
trol’s (CDC) National Healthcare Safety Network for
catheter-related infection (Table 2) [30]. Thereby we will
use probable definitions based on the CDC and the
Dutch surveillance system ‘Prevention of Nosocomial
Infections through Surveillance’ (Table 3) [31].
Patient selection
We will include all patient (≥18 years old) admitted to in-
ternal medicine and subspecialties (gastroenterology &
hepatology, geriatrics, pulmonology and rheumatology)
and all nonsurgical patients admitted to acute medical
units, who receive urinary and/or (peripheral and/or
central) intravenous catheter. Patients admitted for elect-
ive short stay, terminally ill patients and patients who had
all catheters prior to admission will be excluded (Fig. 2).
Primary and secondary endpoints
The primary endpoint is the percentage of patients with
an inappropriate indication for urinary and intravenous
catheter on the days of data collection. Secondary end-
points are catheter-related infections and other compli-
cations, catheter reinsertion rate, use of antibiotics,
length of hospital stay (and ICU) in days, in hospital
mortality, and costs of the de-implementation strategy
and the main healthcare costs.
Assessments
The presence and indications for the catheter use will be
extracted from the medical records in combination with
observations of the admitted patients. During the day of
measurement the indication of the urinary and/or intra-
venous catheter and some patient variables will be
collected. If there is an unclear indication of a catheter,
the investigator will contact one of the healthcare
workers (HCWs) to verify this information.
After discharge, the occurrence of catheter-related infec-
tions (see Table 3 for definitions) [31], with diagnostics
and treatment, or other catheter-related complications
(measured in registry and by investigator), the number of
catheter days, reinsertion rate, use of alternatives for an
indwelling urinary catheter (continence garments, con-
dom catheters, intermittent straight catheterization),
Table 1 List of appropriate indications
Urinary catheter Peripheral intravenous catheter Central intravenous catheter
Acute urinary retention or bladder outlet
obstruction (≥150 cc)
Delivery of peripherally compatible
infusate (IV fluids and medications),
at least once in 24 h
Delivery of non-peripherally compatible infusate (e.g.,
irritants or vesicants), regardless of proposed duration
of use
Accurate measurements of urinary output in
critically ill patients required for treatment
Transfusion of blood and blood
products
PICC : delivery of peripherally compatible infusate, with a
duration of use which will likely confine≥ 6 daysb
Volume measurements of urine output aim for
diagnostics (24 h urine), which cannot be
assessed by other collection strategies
Injection of contrast fluids Invasive hemodynamic monitoring or requirement to
obtain central venous access in critically ill patients
-Nontunneled CVC : duration of use will likely confine
< 15 days
-PICC : duration of use will likely confine≥ 15 days
Assist in healing of open sacral or perineal
wounds in patients with urinary incontinence
Intravenous access for cardiac
dysrhythmia
PICC : Delivery of cyclical or episodic chemotherapy that
can be administered through a peripheral vein, provided
that the proposed duration of such treatment is ≥3 months
Continuous bladder irrigation for hematuria PIVC : duration of use will likely
confine≤ 5 days
Frequent phlebotomy (every 8 h), provided that the proposed
duration of such use is ≥6 days
Patient requires prolonged immobilization Midline : duration of use will likely
confine≤ 14 daysa
PICC : Intermittent infusions or infrequent phlebotomy in
patients with poor/difficult peripheral venous access,
provided that the proposed duration of such use is ≥ 6 days
Palliative care for terminally ill if needed PICC: For infusions or palliative treatment during end-of-life care
Pre- or postoperative according (local) protocol Tunneled catheter or port : preferred if proposed duration
is ≥ 31 day
aUse of PIVCs is preferred over use of midlines for infusion of peripherally compatible infusates up to 5 days
bUse of PIVCs or midlines is preferred over use of PICCs for infusion of peripherally compatible infusates up to 14 days
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reason for admission, Charlson comorbidity index [32],
duration of hospital (and ICU) stay, readmission within
30 days after discharge, and mortality (in hospital or
within 30 days after discharge) will be collected from
(electronic) medical- and nursing records. Furthermore,
the nurse-to-patient ratios and the clinical work experi-
ence of residents will be collected.
De-implementation strategy
We will use a bundle of interventions (Table 4), since it
is known that multiple and well-organized interventions
result into better improvements. The main intervention
is the dissemination of the list of appropriate indications
(Table 1), which will restrict the insertion of urinary and
intravenous catheters by physicians and nurses. The rec-
ommendation will be to remove the catheters without or
with an expired valid indication. A local ‘champion’ (one
of the leading physicians) will be appointed to be
responsible for the interventions in his or her department.
The intervention period will start with a kick-off meeting,
where a list of baseline data of the intervention hospital in
comparison with the other study hospitals will be pre-
sented as a competitive feedback report [33]. If desired,
feedback reports per department could be sent by e-mail
to local investigators. Thereby two educational meetings
about insertion, care and maintenance of urinary and
intravenous catheters will be applied to change HCWs be-
havior. Furthermore, HCWs will be encouraged and
reminded to remove inappropriate catheters by posters,
pocket cards and e-mail messages. In addition to other
studies, patients will be actively supported by education
material to participate in their treatment.
Subsequently, all impeded and promoted factors of
this de-implementation strategy for both HCWs and
Table 2 Definition of catheter-related infections [30]
Catheter-related infection Definition
Healthcare-associated infection (HAI) Infection where the date of event occurs on or after the 3rd calendar day of admission to an
inpatient location, where calendar day 1 is the day of admission
Laboratory-confirmed bloodstream infection (LCBI) Criterion 1: Patient has a recognized pathogen identified from one or more blood
specimens by a culture or non-culture based microbiologic testing method which is
performed for purposes of clinical diagnosis or treatment AND organism(s) identified in
blood is not related to an infection at another site
Criterion 2: Patient has at least one of the following signs or symptoms: fever >38.0 °C,
chills, or hypotension AND organism(s) identified from blood is not related to an
infection at another site AND the same common commensal (i.e., diphtheroids
[Corynebacterium spp. not C. diphtheriae], Bacillus spp. [not B. anthracis], Propionibacterium
spp., coagulase-negative staphylococci [including S. epidermidis], viridans group streptococci,
Aerococcus spp., and Micrococcus spp.) is identified from two or more blood specimens
drawn on separate occasions
Central line An intravascular catheter that terminates at or close to the heart or in one of the great vessels
(aorta, pulmonary artery, superior vena cava, inferior vena cava, brachiocephalic veins, internal
jugular veins, subclavian veins, external iliac veins, common iliac veins, femoral veins) which is
used for infusion, withdrawal of blood, or hemodynamic monitoring
Central line-associated BSI (CLABSI) A LCBI where the central line was in place for >2 calendar days on the date of event, with
day of device placement being Day 1, AND the central line was also in place on the date
of event or the day before
Arterial or venous infection (VASC) It must meet at least one of the following criteria:
1. Patient has organisms from extracted arteries or veins identified by a culture or non-culture
based microbiologic testing method which is performed for purposes of clinical diagnosis
or treatment.
2. Patient has evidence of arterial or venous infection on gross anatomic or histopathologic exam.
3. Patient has at least one of the following signs or symptoms: fever (>38.0 °C), pain, erythema,
or heat at involved vascular site AND more than 15 colonies cultured from intravascular
cannula tip using semiquantitative culture method.
4. Patient has purulent drainage at involved vascular site.
Urinary tract infection (UTI) Patient has at least one of the following signs or symptoms: fever >38.0 °C, suprapubic
tenderness, costovertebral angle pain or tenderness, urinary urgency, urinary frequency,
dysuriaa AND urine culture with no more than two species of organisms identified, at least
one of which is a bacterium of ≥105 CFU/ml
Indwelling catheter (Foley catheter) A drainage tube that is inserted into the urinary bladder through the urethra, is left in place,
and is connected to a drainage bag.
Catheter-associated UTI (CAUTI) A UTI where an indwelling urinary catheter was in place for >2 calendar days on the date
of event, with day of device placement being Day 1, AND an indwelling urinary catheter
was in place on the date of event or the day before
aAn indwelling urinary catheter in place could cause patient complaints of frequency, urgency, or dysuria, and therefore these cannot be used as symptoms when
catheter is in place
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patients will be evaluated by direct observations and
interviews. Additional prevention strategies could be
applied based on these affecting factors and local condi-
tions in the different hospitals.
If this de-implementation strategy prove to be effect-
ive, persistent awareness of the local ‘champion’ in
combination with recurrent surveillance of the appropri-
ate use of catheters and catheter-related infections will
improve the sustainability. Thereby the de-implementation
rule “No indication = Remove catheter” will be recom-
mended in national guidelines and local protocols.
Sample size
The sample size is based on the objective of a 25–50%
reduction in the number of invalid indications for both
urinary and peripheral intravenous catheters, with a
power of 80% and an alpha of 0.05. We excluded CVCs
in the sample size, since the use of CVCs in the internal
medicine and subspecialties departments is infrequent,
but we will include all patients with a CVC in the study.
We used the incidence of inappropriate use of the cathe-
ters from previous results in similar healthcare systems,
Table 3 Probable definition of catheter-related infections [31]
Catheter-related infection Definition
Probable laboratory-confirmed bloodstream
infection (LCBI)
Patient has at least one of the following signs or symptoms: fever >38.0 °C, chills, or hypotension AND
organism(s) identified from (peripheral) blood or catheter segment is not related to an infection at
another site AND defervescence within 48 h of catheter removal or initiation of appropriate
antibiotic therapy
Probable central line-associated BSI
(CLABSI)
A probable LCBI where the central line was in place for >2 calendar days on the date of event, with
day of device placement being Day 1, AND the central line was also in place on the date of event
or the day before
Phlebitis Local pain, warmth, tenderness, erythema, and a palpable cord along the vein OR by positive
sonographic examination in conjunction with erythema and edema of the extremity
Probable urinary tract infection (UTI) Patient has at least two of the following signs or symptoms: fever >38.0 °C, suprapubic tenderness,
costovertebral angle pain or tenderness, urinary urgency, urinary frequency, dysuriaa AND positive
nitrite or leukocyte esterase dipstick test OR pyuria (>10 leukocytes/mm3) OR organism(s) seen in
gram straining in not centrifuged urine OR two sequential urine culture (≥102 CFU/ml) with the
same uropathogens (gram negative bacteria or S. saprophyticus) OR urine culture with one species
of organism identified (≤105 CFU/ml) in a patient treated with
appropriate antibiotic therapy OR the diagnose ‘urinary tract infection’ by doctor OR doctor starts
appropriate antibiotic therapy
Probable catheter-associated UTI (CAUTI) A probable UTI where an indwelling urinary catheter was in place on the date of event or the 7 days before
aAn indwelling urinary catheter in place could cause patient complaints of frequency, urgency, or dysuria, and therefore these cannot be used as symptoms when
catheter is in place
Fig. 2 Flowchart of patient inclusion
Table 4 De-implementation strategy
Interventions of de-implementation strategy
List of appropriate indications
Local ‘champion’
Kick-off meeting, including competitive feedback report of baseline data
Education meeting for healthcare workers
Education materials (e.g., posters, pocket cards)
Patient education materials
Optional interventions based on baseline data and local conditions per
hospital
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which is 40% in urinary catheters [2, 20] and 50% in
PIVC [13]. This results in 91–376 patients with a urinary
catheter, and 66–284 patients with a PIVC. Correlating
for 10–15% missing data the sample size is set to
respectively 105–410 and 75–300 patients in both pre-
and post-intervention group. This will result in a total
sample size of 210–820 patients with a urinary catheter
and 150–600 patients with a PIVC. We aim to include
this number of patients in each hospital to evaluate the
effect of the interventions in each individual hospital.
Statistical analysis
Effect evaluation will be performed using SPSS statistics
23. Categorical variables will be presented as frequencies
and percentages, and continuous variables as means
(with a standard deviation) or medians (with an inter-
quartile range) depending on the data distribution. We
will use segmented regression analysis of interrupted
time series methods to evaluate the differences between
the baseline and intervention group [34, 35]. The data
will be adjusted for possible confounders, autocorrel-
ation and the underlying secular trend. We will perform
stratified analyses to evaluate the impact of the de-im-
plementation strategy in subpopulations. Figures will be
used to visualize the underlying secular trend and the
impact of the de-implementation strategy. The differ-
ence will also be presented in unadjusted and adjusted
rate ratio (RR) with a 95% confidence interval (CI). Dif-
ferences are considered to be statistically significant with
a p < 0.05.
Economic evaluation
The main question for the economic evaluation is if the
benefits of a reduction in inappropriate use of catheters,
which probably lead to a reduction in catheter-related in-
fections, length of stay and associated costs, outweighed
the costs associated with this de-implementation strategy.
For feasibility reasons, we will use length of stay on
general and ICU wards, readmission within 30 days of
discharge, catheter-related complications, representing the
main features of the healthcare system, and productivity
costs for societal perspective. We will estimate the unit
costs for healthcare service based on the prices in the
Dutch guideline on healthcare costs [36]. We will divide
the de-implementation costs in non-recurrent and recur-
rent costs. The non-recurrent costs are study-related, such
as the costs of development of the de-implementation
strategy, material costs, and costs of evaluation of the
de-implementation. Recurrent costs are the costs to
implement the de-implementation strategy. The primary
analysis is a cost-effectiveness analysis, in which the differ-
ence in costs of the de-implementation and outcomes
between the baseline and intervention group will be esti-
mate using incremental cost-effectiveness ratios (ICERs).
The cost-benefit analysis will be reported as the ratio of
de-implementation costs to reduction of healthcare costs
(de-implementation costs < reduction healthcare costs).
Statistical uncertainty will be evaluated in sensitivity ana-
lyses, such as unit costs, preference weights, estimates of
effectiveness and discount rate. The result from the eco-
nomic evaluation will be extrapolated to the national level
using a budget impact analysis according to the principles
of the report of the International Society for Pharmacoe-
conomics and Outcome Research Task Force [37], con-
ducted from societal perspective and health insurance or
national health service perspective.
Discussion
This study protocol describes the design, de-
implementation strategy and evaluation of the ‘Reduce
the inappropriate use of urinary and intravenous
catheters’ (RICAT)-study. It could prevent the in-
appropriate use of urinary and intravenous catheters.
If cost-effective it provides a tool for a nationwide
approach to reduce catheter-related infections and
healthcare costs.
A potential limitation of an interrupted time series
design is the nonexistence of a control group. However,
this quasi-experimental design is considered to be one of
the most effective and powerful designs when
randomization is not desirable or possible [34]. Another
limitation is the inability to evaluate the impact of an
individual intervention. In order to estimate the impact
of a single de-implementation strategy there should be
enough time between the different intervention periods,
which is not possible in our study. Nevertheless, the inter-
ventions are well suitable for a broad de-implementation
in other hospitals.
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